Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications.
about
The neuropsychopharmacology of fronto-executive function: monoaminergic modulationInvolvment of cytosolic and mitochondrial GSK-3beta in mitochondrial dysfunction and neuronal cell death of MPTP/MPP-treated neuronsNEUROBIOLOGY OF ADULT AND TEENAGE SUICIDEEffects of dextroamphetamine, lithium chloride, sodium valproate and carbamazepine on intraplatelet Ca2+ levels.Enhancing synaptic plasticity and cellular resilience to develop novel, improved treatments for mood disorders.Mood regulation in bipolar disorders viewed through the pendulum dynamics concept.Mood stabilizer psychopharmacologyMolecular signatures of peripheral blood mononuclear cells during chronic interferon-α treatment: relationship with depression and fatigue.The wnt pathway in mood disordersDecreased protein kinase C (PKC) in platelets of pediatric bipolar patients: effect of treatment with mood stabilizing drugsEffect of Tamoxifen and Lithium on Treatment of Acute Mania Symptoms in Children and Adolescents.Early intervention in bipolar disorder, part II: therapeuticsBiological basis of suicide and suicidal behaviorProtein kinase C, an elusive therapeutic target?Ameliorating prefrontal cortical dysfunction in mental illness: inhibition of phosphotidyl inositol-protein kinase C signaling.A review of the preclinical and clinical evidence for protein kinase C as a target for drug development for bipolar disorder.Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage.Neuroprotective effects of psychotropic drugs in Huntington's diseaseLithium regulates keratinocyte proliferation via glycogen synthase kinase 3 and NFAT2 (nuclear factor of activated T cells 2)Effects of valproate on serotonin-induced intracellular calcium mobilization in human platelets.Inositol depletion, GSK3 inhibition and bipolar disorder.
P2860
Q24629562-EDAC6948-5E09-4F27-B1EA-BAC59F646B57Q33442821-C02F95DA-9F2B-4995-A6E1-E9EA3FE97BF6Q34695129-AA498D54-1DAD-4F91-87CA-D987ED8E8126Q35101563-EA26E3E0-038C-4D5E-A879-970863B68574Q35236446-D4C17111-51F1-4E14-814A-659553FE41C8Q35675370-21E704DB-1A67-4306-AB5F-80B59739AA8AQ36031634-BCF1FA25-1DDC-4CD7-B193-8BA83849B76EQ36206254-CF2BFDB5-940C-44C8-9647-63735DF8312CQ36310513-C8B03AC0-FCC8-4B06-97E9-540A6723E091Q36360802-93E7653C-0DDC-497D-ADFA-D7F44179B0B2Q36947163-C7B7ED86-1AFE-41B3-A0BE-A1217038D5D2Q37071007-CAE2E736-9538-4BEA-BDB7-026590FBBEEAQ37111899-0A3C79BD-41DF-4735-90DA-B3E0B5E683ABQ37141320-045D4830-63E5-43BC-A469-4295EE08850DQ37249390-876FA124-0DDF-4222-95DD-B95C21904D5AQ37307014-ED1B7408-E6FF-41A8-AF07-E0ECA1FFB55FQ37425341-59297D9F-BDE5-4BD7-B011-E395E9572954Q38163877-48E5E634-A286-4319-A680-87471DAF7A5CQ39523628-E6515450-F254-4BD8-91D7-33AA778AE9D4Q43024788-B0B73657-744A-4BD0-BCD2-FEC91D7A4C99Q48056810-D75CE834-A9F7-48CA-BAA4-36C2FF515602
P2860
Modulation of CNS signal transduction pathways and gene expression by mood-stabilizing agents: therapeutic implications.
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Modulation of CNS signal trans ...... nts: therapeutic implications.
@ast
Modulation of CNS signal trans ...... nts: therapeutic implications.
@en
Modulation of CNS signal trans ...... nts: therapeutic implications.
@nl
type
label
Modulation of CNS signal trans ...... nts: therapeutic implications.
@ast
Modulation of CNS signal trans ...... nts: therapeutic implications.
@en
Modulation of CNS signal trans ...... nts: therapeutic implications.
@nl
prefLabel
Modulation of CNS signal trans ...... nts: therapeutic implications.
@ast
Modulation of CNS signal trans ...... nts: therapeutic implications.
@en
Modulation of CNS signal trans ...... nts: therapeutic implications.
@nl
P2093
P1476
Modulation of CNS signal trans ...... nts: therapeutic implications.
@en
P2093
P304
27-39; discussion 40-1, 113-6
P478
60 Suppl 2
P577
1999-01-01T00:00:00Z